Article Figures & Data
Figures
- FIGURE 1.
Neither mean, median, nor range of SUVmax of 68Ga-FAPI-04 PET differs significantly between primary tumors and metastases.
- FIGURE 2.
Average SUVmax of 68Ga-FAPI PET/CT in various tumor entities. Low, intermediate, and high uptake was defined by cutoff at SUVs 6 and 12. By comparison, average background (blood pool) was found to have SUV 1.4. Ca = cancer; CCC = cholangiocellular carcinoma; CUP = carcinoma of unknown primary; HCC = hepatocellular carcinoma; NET = neuroendocrine tumor.
- FIGURE 3.
Maximum-intensity projections of 68Ga-FAPI PET/CT in patients reflecting 15 different histologically proven tumor entities (sorted by uptake in descending order). Ca = cancer; CCC = cholangiocellular carcinoma; CUP = carcinoma of unknown primary; MTC = medullary thyroid cancer; NET = neuroendocrine tumor.
- FIGURE 4.
Maximum-intensity projection (A) of patient with colorectal carcinoma. Because of low physiologic background uptake, tiny lesions in lung (B) and liver (D) were detected by 68Ga-FAPI-04 PET/CT and measured in dedicated CT of lung (C) and hepatic MRI (E) with long-axis diameters of 1 cm. *Primary tumor in left colon flexure. Red arrow = unspecific uptake in uterus.
- FIGURE 5.
Among others, one clinical application for 68Ga-FAPI PET/CT can be to improve gross tumor volume delineation in preparation for external-beam radiotherapy—in this case, squamous cell carcinoma of neck with local lymph node metastases. From left to right: whole-body maximum-intensity projections, coronal PET slice through head/neck tumor, its fusion with coregistered CT, PET-segmented target-volume definition for external-beam radiotherapy.
Jump to section
Related Articles
Cited By...
- Theranostics in Perspective: White Paper
- Early 10-Minute Postinjection [18F]F-FAPI-42 uEXPLORER Total-Body PET/CT Scanning Protocol for Staging Lung Cancer Using HYPER Iterative Reconstruction
- Diagnostic Radiopharmaceutical Trial Design: Is It Time to Change Nomenclature?
- 18F-FAPI PET/CT Imaging in Pneumoconiosis: a new tool for early diagnosis and guiding treatment of pulmonary fibrosis
- Comparison of [68Ga]Ga-Fibroblast Activation Protein Inhibitor-04 and [18F]FDG PET Imaging for Solitary Fibrous Tumor and Preliminary Application of FAP-Targeted Radiopharmaceutical Therapy
- Are FAP Theranostics Really Happening? Will Radiochemistry or Biology Win?
- Preclinical Evaluation of 68Ga/177Lu-Labeled FAP-Targeted Peptide for Tumor Radiopharmaceutical Imaging and Therapy
- PD-1 cis-targeted IL-2v in combination with radiotherapy inhibits lung cancer growth and remodels the immune microenvironment
- Development of FAP-targeted theranostics discovered by next-generation sequencing-augmented mining of a novel immunized VNAR library
- SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET
- [18F]FDG and [68Ga]Ga-FAPI-04-Directed Imaging for Outcome Prediction in Patients with High-Grade Neuroendocrine Neoplasms
- Addressing Biological Questions with Preclinical Cancer Imaging
- 1,090 Publications and 5 Years Later: Is FAP-Targeted Theranostics Really Happening?
- Optimizing the Therapeutic Index of sdAb-Based Radiopharmaceuticals Using Pretargeting
- Design of a Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy with High Tumor-to-Healthy-Tissue Ratios
- The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma: A Comparison of Tissue, 68Ga-FAPI-46 PET Data, and Survival Data
- 68Ga-Fibroblast Activation Protein Inhibitor PET/CT Improves Detection of Intermediate and Low-Grade Sarcomas and Identifies Candidates for Radiopharmaceutical Therapy
- 68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG
- Diagnostic Potential of Supplemental Static and Dynamic 68Ga-FAPI-46 PET for Primary 18F-FDG-Negative Pulmonary Lesions
- A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET/CT in Genitourinary Cancers
- Overexpression of Fibroblast Activation Protein (FAP) in stroma of proliferative inflammatory atrophy (PIA) and primary adenocarcinoma of the prostate
- 68Ga-FAPI-04 PET/CT in Non-Small Cell Lung Cancer: Accurate Evaluation of Lymph Node Metastasis and Correlation with Fibroblast Activation Protein Expression
- 68Ga-FAPI PET/CT as an Alternative to 18F-FDG PET/CT in the Imaging of Invasive Lobular Breast Carcinoma
- The Current and Future Roles of Precision Oncology in Advanced Breast Cancer
- Diagnostic Accuracy of 68Ga-FAPI Versus 18F-FDG PET in Patients with Various Malignancies
- Imaging of Tumor Stroma Using 68Ga-FAPI PET/CT to Improve Diagnostic Accuracy of Primary Tumors in Head and Neck Cancer of Unknown Primary: A Comparative Imaging Trial
- Design, Preclinical Evaluation, and Clinical Translation of 68Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma
- Metabolic and molecular imaging in inflammatory arthritis
- Fibroblast Activation Protein {alpha}-Directed Imaging and Therapy of Solitary Fibrous Tumor
- Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer
- Imaging Agents for PET of Inflammatory Bowel Disease: A Review
- Oncologic Staging with 68Ga-FAPI PET/CT Demonstrates a Lower Rate of Nonspecific Lymph Node Findings Than 18F-FDG PET/CT
- Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in a Cohort of 226 Patients with Various Cancers
- PET imaging of fibroblast activation protein alpha (FAP) detects incipient cardiotoxicity due to anthracycline chemotherapy
- Fibroblast Activation Protein and Glycolysis in Lymphoma Diagnosis: Comparison of 68Ga-FAPI PET/CT and 18F-FDG PET/CT
- Performance of 68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT in Evaluation of Erdheim-Chester Disease: A Comparison with 18F-FDG PET/CT
- Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy
- Molecular Imaging of Myocardial Fibroblast Activation in Patients with Advanced Aortic Stenosis Before Transcatheter Aortic Valve Replacement: A Pilot Study
- Clinical Evaluation of 68Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin {alpha}v{beta}3 in Various Cancer Types
- Tumor Characterization by [68Ga]FAPI-46 PET/CT Can Improve Treatment Selection for Pancreatic Cancer Patients: An Interim Analysis of a Prospective Clinical Trial
- Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions
- Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy
- Molecular Imaging of Myocardial Fibroblast Activation in Patients with Advanced Aortic Stenosis Before Transcatheter Aortic Valve Replacement: A Pilot Study
- Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions
- Fibroblast Activation Protein Inhibitor-Based Radionuclide Therapies: Current Status and Future Directions
- 18F-FDG PET/CT in the Management of Osteosarcoma
- 68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study
- 18F-FDG PET/CT in the Management of Osteosarcoma
- Clinical Evaluation of 68Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin {alpha}v{beta}3 in Various Cancer Types
- Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities
- Fibroblast Activation Protein-Targeted Radioligand Therapy for Treatment of Solid Tumors
- Three-Time-Point PET Analysis of 68Ga-FAPI-46 in a Variety of Cancers
- PET Imaging of Fibroblast Activation Protein in Various Types of Cancer Using 68Ga-FAP-2286: Comparison with 18F-FDG and 68Ga-FAPI-46 in a Single-Center, Prospective Study
- Static and Dynamic 68Ga-FAPI PET/CT for the Detection of Malignant Transformation of Intraductal Papillary Mucinous Neoplasia of the Pancreas
- Spontaneous, naturally occurring cancers in non-human primates as a translational model for cancer immunotherapy
- FAP-retargeted Ad5 enables in vivo gene delivery to stromal cells in the tumor microenvironment
- Fibroblast Activation Protein Inhibitor Imaging in Nonmalignant Diseases: A New Perspective for Molecular Imaging
- A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake
- Repetitive Early 68Ga-FAPI PET Acquisition Comparing 68Ga-FAPI-02, 68Ga-FAPI-46, and 68Ga-FAPI-74: Methodologic and Diagnostic Implications for Malignant, Inflammatory/Reactive, and Degenerative Lesions
- Staging Liver Fibrosis by Fibroblast Activation Protein Inhibitor PET in a Human-Sized Swine Model
- Dual-Tracer PET/CT Protocol with [18F]-FDG and [68Ga]Ga-FAPI-46 for Cancer Imaging: A Proof of Concept
- Generation and in vivo validation of an IL-12 fusion protein based on a novel anti-human FAP monoclonal antibody
- Cardiac Fibroblast Activation in Patients Early After Acute Myocardial Infarction: Integration with MR Tissue Characterization and Subsequent Functional Outcome
- Head-to-Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT for Evaluation of Head and Neck Squamous Cell Carcinoma: A Single-Center Exploratory Study
- Correlation of 68Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study
- Pitfalls and Common Findings in 68Ga-FAPI PET: A Pictorial Analysis
- The Added Value of 68Ga-FAPI PET/CT in Patients with Head and Neck Cancer of Unknown Primary with 18F-FDG-Negative Findings
- Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy
- Initial Clinical Experience with 90Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients
- A mass spectrometry-based method for the determination of in vivo biodistribution of tumor targeting small molecule-metal conjugates
- Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results
- A novel dimeric FAP-targeting small molecule-radio conjugate with high and prolonged tumour uptake
- Detecting Fibroblast Activation Proteins in Lymphoma Using 68Ga-FAPI PET/CT
- 68Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with 18F-FDG PET/CT
- Fibroblast Activation Protein-Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study